CARDOPA

DOPAMINE HYDROCHLORIDE

Dopamine is recommended for the correction of haemodynamic imbalance present in- Acute hypotension or shock associated with myocardial infarction, endotoxic septicaemia, trauma and renal failure. As an adjunct after open heart surgery, where there is persistent hypotension after correction of hypovolaemia. In chronic cardiac decompensation as in congestive failure.

Inotropic-sympathomimetics

Dopamine stimulates dopaminergic receptors at lower doses producing renal and mesenteric vasodilation; at higher doses stimulates both dopaminergic and 81-adrenergic receptors producing cardiac stimulation and renal vasodilation; large doses stimulates 8-adrenergic receptors.

Intravenous- Acute heart failure: Adult: Initially, 2-5 mcg/kg/min, increased gradually by up to 5-10 mcg/kg/min according to patient8s cardiac and urine output. Seriously ill patient: Up to 20-50 mcg/kg/min may be required.

Cyclopropane and halogenated hydrocarbon anaesth may enhance the arrhythmogenic effect of dopamine. Cardiac effects are antagonised by 8-adrenergic agents (e.g. propanolol, metoprolol). 8-adrenergic blocking agents may antagonise the vasoconstricting effect of high dose dopamine. Prolonged and enhanced effect with MAOIs. Risk of hypotension and bradycardia with phenytoin. May potentiate diuretic effect of hydrochlorothiazide or furosemide. Enhanced vasopressor effect with TCAs and guanethidine. Risk of excessive vasoconstriction with ergot alkaloids.

Administration of dopamine is contraindicated in the following cases: Pheochromocytoma, atrial or ventricular tachyarrhythmias, ventricular fibrillation, hyperthyroidism, concurrent use with ergotamine.

Ectopic heartbeats, angina, tachycardia, palpitation, hypotension, vasoconstriction, dyspnoea, nausea, vomiting, headache, cardiac conduction abnormalities, HTN, azotemia, anxiety, widened QRS complex, bradycardia, piloerection, peripheral cyanosis.

Pregnancy: It is not known whether dopamine crosses the placental barrier. The benefits of using this product should be weighed against the possible risks to the fetus. Lactation: It is not recommended for breast-feeding mothers unless the expected benefits outweigh any potential risks.

Symptoms: Excessive BP elevation, vasoconstriction. Management: Reduce dose or discontinue infusion. May also consider infusion of phentolamine mesylate.

Patient with CV disease, cardiac arrhythmias and/or occlusive vascular disease, active myocardial ischaemia or recent MI. Correct hypovolaemia prior to treatment. Pregnancy and lactation.

Store below 30 8C and protect from light.